Deutsche Bank Has Buy Recommendation on Cigna (CI)
The Cigna Group (NYSE:CI) is one of the 13 Deep Value Stocks to Buy Right Now.
Deutsche Bank, on February 10, increased its target price on Cigna by 1.0% to $304 (from $301) and retained its Buy recommendation on the stock. The firm views the company’s guidance for FY 2026 and the company’s settlement with the US Federal Trade Commission (FTC) as “possibly clearing event[s].”
For reference, Cigna, on February 5, released its Q4 2025 earnings report. Included in this report was management’s outlook for 2026. They are targeting ~2% YoY growth in revenues, which they expect to translate to ~1.5% YoY growth in adjusted operating income per share.
As for the deal with the US FTC, Reuters reported on February 4 that Cigna Corp’s Express Scripts reached a settlement with the FTC regarding the company’s insulin pricing practices. As part of the settlement, the company is restricted for 10 years from engaging in certain practices, such as pocketing rebate payments from drugmakers based on the list price of the drugs. The FTC thinks that this agreement will save consumers $7 billion over the course of 10 years.
The Cigna Group (NYSE:CI) provides health services globally through Evernorth Health Services and Cigna Healthcare. The company is based in Bloomfield, Connecticut, and was founded in 1792.
While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Disclosure: None.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jefferies Cuts United Airlines (UAL) Target to $148, Sees Strong Travel Demand

BofA Boosts Carlyle (CG) Target amid Broader Asset Manager Estimate Revisions


Barclays Lowers Humana (HUM) Price Target amid Questions on Margin Expansion Outlook

